Short stature Homeobox-containing gene (SHOX) Deficiency
What is SHOX?
- SHOX is an acronym for the short stature homeobox-containing gene.
- The SHOX gene codes for a key transcription factor that plays a critical role in controlling human stature primarily through regulation of chondrocyte development.1
- The SHOX gene is located on the human sex chromosomes (X and Y), and two functional copies of the gene are required for normal growth.
What is SHOX Deficiency?
- SHOX deficiency (SHOX-D) is present when one copy (or very rarely, both copies) of the SHOX gene has undergone deletion or mutation.
- SHOX deficiency may be inherited in a dominant fashion from an affected parent and passed on to offspring, or may occur spontaneously in a family with no other affected members.
- Patients with SHOX deficiency may present with a broad phenotypic spectrum ranging from isolated short stature with no distinguishing clinical features* to short stature with moderate to severe skeletal dysplasia (Léri-Weill syndrome).2
*approximately 2-3% of patients with clinical features consistent with idiopathic short stature may test positive for SHOX deficiency.3
Potential Indicators of SHOX Deficiency
Clinical features that may be associated with SHOX deficiency include:2,4
- Disproportionate short stature (greater shortening of the limbs than trunk)
- High-arched palate
- Cubitus valgus (increased carrying angle of the elbow)
- Madelung (dinner fork) wrist deformity
- Bowing of the forearm or tibia
- Appearance of muscular hypertrophy in the calves
- Family history of Léri-Weill syndrome (or Langer syndrome, a very rare disorder resulting from complete deficiency of both SHOX genes)
- Radiographic anomalies, e.g. triangularization of the radial epiphysis (see figure), radial and/or tibial bowing, shortening of the 4th or 5th metacarpals

Diagnosing SHOX Deficiency
- Diagnostic testing for SHOX deficiency (SHOXDNAdxSM) is available through Esoterix, Inc. (Calabasas Hills, CA).
- Diagnosis of SHOX deficiency clearly identifies the underlying cause of short stature for the patient, family, and health care provider.
- Because SHOX deficiency is a heritable condition, definitive diagnosis of SHOX deficiency may have implications for genetic counseling for the patient and family members.
Efficacy of Humatrope Therapy6
- 52 patients with SHOX deficiency were randomized to either two years of Humatrope treatment at a dose of 0.35 mg/kg/wk (50 μg/kg/day) or non-treatment control.
- Humatrope-treated patients with SHOX deficiency responded with highly significant increases in height velocity and height SDS (figure). Over the 2-year study period, Humatrope-treated patients with SHOX deficiency gained an average of 5.8 cm more in height than untreated patients.
- The response to Humatrope therapy was similar for patients with SHOX deficiency and patients with Turner syndrome.
- No significant Humatrope effect on bone age was observed.

Safety of Humatrope Therapy6
- No new safety concerns were observed in the SHOX-deficient patient population that were not already known.
- No serious adverse events were reported for patients with SHOX deficiency.

References
- Munns CJF, Haase HR, Crowther LM, et al. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab. 2004;89(8):4130-4135.
- Ross JL, Scott C Jr, Marttila P, et al. Phenotypes associated with SHOX deficiency. J Clin Endocrinol Metab. 2001;86(12):5674-5680.
- Rappold GA, Fukami M, Niesler B, et al. Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature. J Clin Endocrinol Metab. 2002;87(3):1402-1406.
- Ross JL, Kowal K, Quigley CA, et al. The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: contrasting children with Léri-Weill dyschondrosteosis and Turner syndrome. J Pediatr. 2005;147:499-507.
- Binder G, Fritsch H, Schweizer R, Ranke MB. Radiological signs of Léri-Weill dyschondrosteosis in Turner syndrome. Horm Res. 2001;55(2):71-76.
- Blum WF, Crowe BJ, Quigley CA, et al. Growth hormone is effective in treatment of short stature associated with SHOX deficiency: two-year results of a randomized, controlled, multi-center trial. J Clin Endocrinol Metab. 2007;92(1):219-228.












